Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer
Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer.…
Browsing Tag
Exelixis
1 post